{"nctId":"NCT01444651","briefTitle":"A Trial of Tadalafil and Glycemic Traits","startDateStruct":{"date":"2011-08"},"conditions":["Cardiovascular Disease","Insulin Resistance","Glucose Intolerance","Obesity"],"count":73,"armGroups":[{"label":"Tadalafil","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tadalafil"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tadalafil","otherNames":["Adcirca, Cialis"]},{"name":"Placebo","otherNames":["Sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age \\> 18 years and \\< 50 years\n* BMI \\> 30 kg/m2\n* Fasting insulin \\> 10 uU/mL\n\nExclusion Criteria:\n\n* Systolic blood pressure (SBP) \\< 100, \\> 150 mmHg\n* Current anti-hypertensive medication use, including diuretics\n* Current use of organic nitrates\n* Current use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)\n* History of reaction to PDE-5 inhibitors\n* Known HIV infection\n* Use of medications that strongly alter CYP3A4 activity\n* History of myocardial infarction, angina, uncontrolled cardiac arrhythmia, stroke, transient ischemic attack, or seizure\n* Known non-arteritic ischemic optic retinopathy (NAIOR)\n* History of hearing loss\n* Estimated glomerular filtration rate (eGFR) \\< 60 ml/min/1.73 m2 by the modified diet in renal disease (MDRD) equation\n* Hepatic transaminase (AST and ALT) levels greater than three times the upper limit of normal\n* Known pregnancy or those unwilling to avoid pregnancy during the course of the study\n* History of priapism\n* Use in excess of four alcoholic drinks daily\n* History of diabetes mellitus or use of anti-diabetic medications\n* Known anemia (men, Hct \\< 38% and women, Hct \\< 36%)","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Insulin Resistance From Baseline to 3 Months, as Measured by HOMA-IR","description":"The primary endpoint is defined as the treatment group difference in the change in insulin resistance (baseline HOMA-IR minus 3-month HOMA-IR). HOMA-IR = \\[fasting glucose \\* fasting insulin\\]/405","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.57","spread":"2.86"},{"groupId":"OG001","value":"3.84","spread":"3.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.81","spread":"5.14"},{"groupId":"OG001","value":"5.06","spread":"3.95"}]}]}]},{"type":"SECONDARY","title":"Baseline to 3-month Change in Insulin Sensitivity, as Measured by the Matsuda Index","description":"The secondary endpoint is defined as the treatment group difference in the change in Matsuda Index (baseline minus 3-month). This index is a measure of insulin resistance derived from a frequently sampled oral glucose tolerance test, obtaining glucose and insulin levels in the fasting state, as well as 30, 60, 90, and 120 min after administration of oral glucose load. Matsuda index = 10,000/SQRT \\[fasting glucose\\*fasting insulin\\* (mean glucose from time 30, 60, 90, 120 min) \\* (mean insulin at time 30, 60, 90, and 120 min)\\]","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"2.54"},{"groupId":"OG001","value":"3.51","spread":"2.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.27","spread":"2.83"},{"groupId":"OG001","value":"3.28","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"Baseline to 3-month Change in Endothelial Function Measured by EndoPAT","description":"Endothelial function was measured using the reactive hyperemia index, acquired using EndoPAT device. Peripheral arterial tonometry probes were placed on both index fingers. After a 5 min equilibration period, a blood pressure cuff was inflated to 200 mmHg and kept inflated for 5 min. The cuff was then rapidly deflated and the reactive hyperemic response pulse volume recorded, where RHI = ratio of hyperemic finger pulse volume (post-cuff inflation / pre-cuff inflation) to control finger pulse volume (post-cuff inflation / pre-cuff inflation)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.5"},{"groupId":"OG001","value":"2.3","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.7"},{"groupId":"OG001","value":"2.2","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Insulinogenic Index","description":"The secondary endpoint is defined as the treatment group difference in the change in insulinogenic index (baseline minus 3-month). This index is thought to reflect insulin secretion, and is derived from fasting and 30 min-post oral glucose tolerance testing glucose and insulin values. Insulinogenic index = \\[fasting insulin - insulin at time 30 min\\] / \\[fasting glucose - glucose at time 30 min\\]","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"8.04"},{"groupId":"OG001","value":"2.17","spread":"2.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":"3.03"},{"groupId":"OG001","value":"1.04","spread":"2.32"}]}]}]},{"type":"SECONDARY","title":"Baseline to 3 Month Change in Composite of Insulin Resistance and Sensitivity, as Measured by the Oral Disposition Index","description":"The secondary endpoint is defined as the treatment group difference in the change in oral disposition index (baseline minus 3-month). This is thought to reflect a composite of both insulin resistance and secretion. Oral disposition index = insulinogenic index / fasting insulin","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.74","spread":"11.56"},{"groupId":"OG001","value":"2.87","spread":"3.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.48","spread":"4.62"},{"groupId":"OG001","value":"0.58","spread":"5.21"}]}]}]},{"type":"SECONDARY","title":"Baseline to 3-month Change in Matsuda Disposition Index","description":"Change in disposition index from baseline to 3 months. This index is a composite measure thought to reflect insulin resistance and secretion. Matsuda disposition index = \\[Matsuda sensitivity index \\* insulinogenic index\\]","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"24.19"},{"groupId":"OG001","value":"6.67","spread":"9.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.22","spread":"8.51"},{"groupId":"OG001","value":"0.19","spread":"18.42"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":["Headache","Back or leg pain","Blurry vision and headache","Headache and back ache","arm pain"]}}}